SG11201701309SA - Chimeric antigen receptors - Google Patents

Chimeric antigen receptors

Info

Publication number: SG11201701309SA
Authority: SG; Singapore
Prior art keywords: chimeric antigen; antigen receptors; receptors; chimeric; antigen
Prior art date: 2014-09-15

Application number

SG11201701309SA

Inventor

Attilio Bondanza

Monica Casucci

Maria Chiara Bonini

Original Assignee

Molmed Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-15

Filing date

2015-09-14

Publication date

2017-04-27

2015-09-14 Application filed by Molmed Spa filed Critical Molmed Spa

2017-04-27 Publication of SG11201701309SA publication Critical patent/SG11201701309SA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4223—CD44 not IgG
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4264—Cancer antigens from embryonic or fetal origin
- A61K40/4266—Carcinoembryonic antigen [CEA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/21—Transmembrane domain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Virology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Mycology (AREA)
Developmental Biology & Embryology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Peptides Or Proteins (AREA)

SG11201701309SA 2014-09-15 2015-09-14 Chimeric antigen receptors SG11201701309SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14184838		2014-09-15
PCT/IB2015/057049 WO2016042461A1 (en)	2014-09-15	2015-09-14	Chimeric antigen receptors

Publications (1)

Publication Number	Publication Date
SG11201701309SA true SG11201701309SA (en)	2017-04-27

Family

ID=51541003

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201701309SA SG11201701309SA (en)	2014-09-15	2015-09-14	Chimeric antigen receptors

Country Status (23)

Country	Link
US (1)	US11299529B2 (en)
EP (3)	EP3194434B1 (en)
JP (1)	JP6684782B2 (en)
KR (1)	KR20170054505A (en)
CN (1)	CN107074930A (en)
AU (1)	AU2015316480B2 (en)
BR (1)	BR112017004949A2 (en)
CA (1)	CA2958807C (en)
CY (1)	CY1122607T1 (en)
DK (2)	DK3575315T3 (en)
ES (2)	ES2933352T3 (en)
HR (1)	HRP20191468T1 (en)
IL (1)	IL251030B (en)
LT (1)	LT3194434T (en)
MX (1)	MX2017003421A (en)
PL (1)	PL3194434T3 (en)
PT (2)	PT3575315T (en)
RU (1)	RU2745705C2 (en)
SG (1)	SG11201701309SA (en)
SI (1)	SI3194434T1 (en)
UA (1)	UA123764C2 (en)
WO (1)	WO2016042461A1 (en)
ZA (1)	ZA201701344B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2948544A4 (en)	2013-01-28	2016-08-03	St Jude Childrens Res Hospital	NKG2D-SPECIFIC CHIMERIC RECEPTOR ADAPTED FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASES
AU2015259877B2 (en)	2014-05-15	2021-02-25	National University Of Singapore	Modified natural killer cells and uses thereof
EP3293199B1 (en)	2016-09-08	2021-01-13	Heinrich-Heine-Universität Düsseldorf	Chimeric antigen receptors
WO2018089829A1 (en) *	2016-11-10	2018-05-17	Fortis Therapeutics, Inc.	Cd46-specific effector cells and uses thereof
KR20240057444A (en)	2017-03-27	2024-05-02	내셔널 유니버시티 오브 싱가포르	Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
CN110494557A (en)	2017-03-27	2019-11-22	新加坡国立大学	For expanding the stimulation cell line with Activated NK Cells in vitro
SG11201909541WA (en)	2017-04-26	2019-11-28	Eureka Therapeutics Inc	Chimeric antibody/t-cell receptor constructs and uses thereof
US11771718B2 (en)	2017-10-18	2023-10-03	Precigen, Inc.	Polypeptide compositions comprising spacers
WO2019090355A1 (en) *	2017-11-06	2019-05-09	Children's National Medical Center	Cells expressing antibodies and methods of treatment using the same
CN109971717B (en) *	2017-12-28	2023-06-20	上海细胞治疗研究院	T cells co-expressing CD40 antibody and mesothelin specific chimeric antigen receptor and uses thereof
WO2019134866A1 (en)	2018-01-03	2019-07-11	Molmed Spa	Chimeric antigen receptors containing optimal spacer region
CN109321530B (en) *	2018-02-12	2021-03-12	华东师范大学	A safe chimeric antigen receptor T cell and its use
US20210046159A1 (en)	2018-03-09	2021-02-18	Ospedale San Raffaele S.R.L.	Il-1 antagonist and toxicity induced by cell therapy
EP3802796A1 (en)	2018-05-30	2021-04-14	Glycostem Therapeutics B.V.	Car nk cells
CN110760005A (en) *	2018-07-25	2020-02-07	上海细胞治疗集团有限公司	Chimeric antigen receptor modified T cell of targeted Glypican-3 antigen and application thereof
EP3917952A4 (en) *	2019-01-28	2022-11-02	Multitude Inc.	Antibodies specific to cd44
AU2020232691B2 (en)	2019-03-05	2023-06-29	Nkarta, Inc.	CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
MX2022000852A (en) *	2019-07-24	2022-02-10	Eureka Therapeutics Inc	CELLS THAT EXPRESS CHIMERIC ANTIGEN RECEPTORS AND CHIMERIC STIMULANT RECEPTORS AND THEIR USES.
CN114057874B (en) *	2020-07-31	2023-05-05	北京市神经外科研究所	anti-CD 44 single-chain antibody and application thereof in preparation of medicines for treating tumors
JP2023534765A (en)	2020-08-07	2023-08-10	フォーティスセラピューティクス，インク．	CD46 targeting immune complexes and methods of use thereof
CA3202112A1 (en) *	2020-12-16	2022-06-23	Matti Korhonen	Chimeric antigen receptor (car) spacer modifications enhance car t cell functionality
EP4263600A1 (en)	2020-12-18	2023-10-25	Century Therapeutics, Inc.	Chimeric antigen receptor systems with adaptable receptor specificity
CN114891111A (en) *	2020-12-31	2022-08-12	中元汇吉生物技术股份有限公司	Protein specifically binding to human IgG4 and application thereof
CN112851794B (en) *	2021-02-04	2023-05-23	苏州铂维生物科技有限公司	Epitope based on CD271 and application thereof
WO2023030393A1 (en) *	2021-09-01	2023-03-09	中国科学院生物物理研究所	Chimeric antigen receptor and use thereof
CN114133457B (en) *	2021-12-08	2022-08-19	郑州源创吉因实业有限公司	Bispecific Chimeric Antigen Receptor (CAR) targeting ROR1 and CD33 and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9803351D0 (en)	1998-02-17	1998-04-15	Oxford Biomedica Ltd	Anti-viral vectors
GB0009760D0 (en)	2000-04-19	2000-06-07	Oxford Biomedica Ltd	Method
GB0221778D0 (en)	2002-09-19	2002-10-30	Molmed Spa	Conjugate
GB0224442D0 (en)	2002-10-21	2002-11-27	Molmed Spa	A delivery system
TWI476001B (en)	2011-12-26	2015-03-11	Ind Tech Res Inst	Trimeric fc fusion and uses thereof
GB201206559D0 (en) *	2012-04-13	2012-05-30	Ucl Business Plc	Polypeptide
AU2013204922B2 (en) *	2012-12-20	2015-05-14	Celgene Corporation	Chimeric antigen receptors
CN103145849B (en)	2013-02-18	2014-06-11	冯振卿	Chimeric antigen receptor and use thereof
AU2014225365B2 (en)	2013-03-07	2019-09-12	Baylor College Of Medicine	Targeting CD138 in cancer
DK3004329T3 (en) *	2013-06-05	2020-05-18	Bellicum Pharmaceuticals Inc	METHODS FOR INDUCTION OF PARTIAL APOPTOSIS USING CASPASE POLYPEPTIDES
CA3001306A1 (en) *	2015-10-09	2017-04-13	Miltenyi Biotec Technology, Inc.	Chimeric antigen receptors and methods of use

2015
- 2015-09-14 PT PT191810175T patent/PT3575315T/en unknown
- 2015-09-14 PL PL15775814T patent/PL3194434T3/en unknown
- 2015-09-14 EP EP15775814.5A patent/EP3194434B1/en active Active
- 2015-09-14 SG SG11201701309SA patent/SG11201701309SA/en unknown
- 2015-09-14 EP EP19181017.5A patent/EP3575315B1/en active Active
- 2015-09-14 DK DK19181017.5T patent/DK3575315T3/en active
- 2015-09-14 KR KR1020177010132A patent/KR20170054505A/en active IP Right Grant
- 2015-09-14 UA UAA201703663A patent/UA123764C2/en unknown
- 2015-09-14 AU AU2015316480A patent/AU2015316480B2/en active Active
- 2015-09-14 ES ES19181017T patent/ES2933352T3/en active Active
- 2015-09-14 MX MX2017003421A patent/MX2017003421A/en unknown
- 2015-09-14 PT PT15775814T patent/PT3194434T/en unknown
- 2015-09-14 CA CA2958807A patent/CA2958807C/en active Active
- 2015-09-14 JP JP2017514352A patent/JP6684782B2/en active Active
- 2015-09-14 SI SI201530863T patent/SI3194434T1/en unknown
- 2015-09-14 EP EP22194958.9A patent/EP4159752A1/en active Pending
- 2015-09-14 BR BR112017004949A patent/BR112017004949A2/en not_active Application Discontinuation
- 2015-09-14 CN CN201580059769.3A patent/CN107074930A/en active Pending
- 2015-09-14 US US15/511,026 patent/US11299529B2/en active Active
- 2015-09-14 ES ES15775814T patent/ES2742528T3/en active Active
- 2015-09-14 RU RU2017112882A patent/RU2745705C2/en active
- 2015-09-14 WO PCT/IB2015/057049 patent/WO2016042461A1/en active Application Filing
- 2015-09-14 DK DK15775814.5T patent/DK3194434T3/en active
- 2015-09-14 LT LTEP15775814.5T patent/LT3194434T/en unknown
2017
- 2017-02-22 ZA ZA2017/01344A patent/ZA201701344B/en unknown
- 2017-03-08 IL IL251030A patent/IL251030B/en unknown
2019
- 2019-08-14 HR HRP20191468 patent/HRP20191468T1/en unknown
- 2019-08-21 CY CY20191100894T patent/CY1122607T1/en unknown

Also Published As

Publication number	Publication date
UA123764C2 (en)	2021-06-02
MX2017003421A (en)	2017-12-07
ES2933352T3 (en)	2023-02-06
JP6684782B2 (en)	2020-04-22
US11299529B2 (en)	2022-04-12
BR112017004949A2 (en)	2017-12-05
LT3194434T (en)	2019-09-25
IL251030A0 (en)	2017-04-30
IL251030B (en)	2021-07-29
PT3575315T (en)	2022-12-16
ZA201701344B (en)	2019-06-26
EP4159752A1 (en)	2023-04-05
RU2017112882A (en)	2018-10-17
HRP20191468T1 (en)	2019-11-29
CN107074930A (en)	2017-08-18
PL3194434T3 (en)	2019-12-31
US20170247428A1 (en)	2017-08-31
JP2017528141A (en)	2017-09-28
DK3194434T3 (en)	2019-08-26
DK3575315T3 (en)	2022-12-19
EP3575315B1 (en)	2022-09-14
SI3194434T1 (en)	2019-11-29
RU2017112882A3 (en)	2019-04-25
AU2015316480A1 (en)	2017-04-06
EP3575315A1 (en)	2019-12-04
EP3194434A1 (en)	2017-07-26
PT3194434T (en)	2019-09-10
EP3194434B1 (en)	2019-06-19
CY1122607T1 (en)	2021-03-12
ES2742528T3 (en)	2020-02-14
RU2745705C2 (en)	2021-03-30
AU2015316480B2 (en)	2021-02-04
CA2958807C (en)	2024-01-09
CA2958807A1 (en)	2016-03-24
KR20170054505A (en)	2017-05-17
WO2016042461A1 (en)	2016-03-24

Publication	Publication Date	Title
IL291292A (en)	2022-05-01	Chimeric antigen receptors targeting cd-19
IL250536A0 (en)	2017-03-30	Chimeric antigen receptors
IL251030A0 (en)	2017-04-30	Chimeric antigen receptors
ZA201704059B (en)	2021-08-25	Bcma chimeric antigen receptors
IL254254A0 (en)	2017-10-31	Chimeric antigen receptor
ZA201700730B (en)	2021-06-30	Bcma chimeric antigen receptors
IL258527A (en)	2018-05-31	Anti-cd30 chimeric antigen receptors
SG11201606790XA (en)	2016-09-29	Chimeric antigen receptor
EP3256496A4 (en)	2018-12-12	Chimeric antigen receptors
GB201503742D0 (en)	2015-04-22	Chimeric antigen receptor
GB201617290D0 (en)	2016-11-23	Novel chimeric antigen receptors
HUE056735T2 (en)	2022-03-28	Mnd promoter chimeric antigen receptors
PT3230310T (en)	2019-09-26	Anti-cd70 chimeric antigen receptors
GB201411420D0 (en)	2014-08-13	Antibody constructs
GB201519900D0 (en)	2015-12-23	Chimeric antigen receptor
GB201409761D0 (en)	2014-07-16	Chimeric antigen receptor
GB201403481D0 (en)	2014-04-16	Chimeric antigen receptor